Silexion Therapeutics Corp (SLXN) Form 8-K — Aug 13, 2026
Silexion Therapeutics closed a public offering on August 13, 2026, selling 2,028,619 ordinary shares and 1,817,542 pre-funded warrants at $0.65 per share alongside 3,846,161 five-year Series E warrants, for gross proceeds of approximately $2.5 million and net proceeds of roughly $2.1 million. H.C. Wainwright & Co. acted as sole placement agent on a best-efforts basis, earning a 7.0% cash fee plus a 1.0% management fee and receiving 269,231 warrants exercisable at $0.8125.
Key figures
- Gross Proceeds
- 2500000
- Offering Price
- 0.65
- Shares Offered
- 2,028,619 ordinary shares plus 1,817,542 pre-funded warrants
- Net Proceeds
- approximately $2.1 million
- Note Conversion Price
- 0.65
- Ordinary Warrant Term
- 5 years
- Note Conversion Shares
- 1153848
- Note Remaining Balance
- 206462
- Expense Reimbursements
- $7,500 non-accountable plus up to $70,000 legal/out-of-pocket
- Placement Agent Cash Fee
- 7.0% of gross proceeds
- Ordinary Warrants Issued
- 3846161
- Placement Agent Warrants
- 269231
- Note Conversion Principal
- 750001
- Placement Agent Management Fee
- 1.0% of gross proceeds
- Ordinary Warrant Exercise Price
- 0.65
- Pre Funded Warrant Exercise Price
- 0.0001
- Placement Agent Warrant Exercise Price
- 0.8125
- Estimated Adjusted Shareholders Equity
- approximately $3.2 million as of June 30, 2026
- Pre Funded Warrant Exercise Shares Issued
- 823770
Price after filing
Close on the filing date to close N calendar days later (from $0.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.